{"organizations": [], "uuid": "34e4e2d3422fb3857fe95f04507e217cae7c0032", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/regeneron-brief/brief-novartis-files-patent-infringement-against-regeneron-over-latters-manufacture-of-eylea-zaltrap-idUSL1N1R11VO", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis files patent infringement against Regeneron over latter's manufacture of Eylea, Zaltrap", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T22:59:00.000+02:00", "replies_count": 0, "uuid": "34e4e2d3422fb3857fe95f04507e217cae7c0032"}, "author": "", "url": "https://www.reuters.com/article/regeneron-brief/brief-novartis-files-patent-infringement-against-regeneron-over-latters-manufacture-of-eylea-zaltrap-idUSL1N1R11VO", "ord_in_thread": 0, "title": "BRIEF-Novartis files patent infringement against Regeneron over latter's manufacture of Eylea, Zaltrap", "locations": [], "entities": {"persons": [], "locations": [{"name": "eylea", "sentiment": "none"}], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "zaltrap reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 9:00 PM / in 15 minutes BRIEF-Novartis files patent infringement against Regeneron over latter's manufacture of Eylea, Zaltrap Reuters Staff 1 Min Read March 19 (Reuters) - Novartis files patent infringement lawsuit against regeneron over latter’s manufacturing of eylea, zaltrap — court filing Novartis alleges that eylea, zaltrap incorporate technology covered by one or more claims of a patent it holds Novartis says the patent in question dates from 1997 and is called ‘vector for expression of a polypeptide in a mammalian cell’ Novartis seeks compensatory and triple damages for renegeron’s alleged willful patent infringement, in a lawsuit filed with the u.s. District court in manhattan", "external_links": [], "published": "2018-03-19T22:59:00.000+02:00", "crawled": "2018-03-19T23:17:52.008+02:00", "highlightTitle": ""}